Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug

Eli Lilly has paid 80 million ($81 million) upfront for the worldwide rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models.